On April 30, I proudly kicked off the inaugural Digital Health for Pharma (DH4P) annual conference on behalf of Evolution Road. In the early days of digital marketing I had the pleasure of chairing the ePharma Summit which was a great way for the life science industry to come together and learn, share and connect with one another. With so many similarities between the evolution of digital marketing and the current and likely future path of digital health, we believed there was a need to create the first conference specifically focused on how life science companies can drive commercial value through digital health.
The speaker faculty was unparalleled, particularly for a first year conference. Many Pharmaceutical manufacturers attended including Pfizer, GSK, BMS, Celgene, Sanofi, Novo Nordisk, Bayer, UCB, Boehringer Ingelheim, Ferring, Lifescan, Novartis, BTG, Irwonwood, Abbvie, Roche, Adhera Therapeutics and others. We also gained diverse perspectives from healthcare provider and payer organizations such as Humana, Highmark and Jefferson Health as well as from digital health companies such as Akili, Propeller, Click Therapeutics and PackHealth.
We created the conference to support the dialogue about digital health value models for life sciences. Here is an overview of the different types of value models that we shared at DH4P:
INVEST: Equity investments in digital health companies via corporate pharma venture or innovation funds, Acquisition (i.e., Roche’s acquisition of FlatIron), Joint Venture (i.e., Sanofi + Verily forming Onduo)
INCUBATE / ACCELERATE: Internal efforts to support digital health startups (i.e., JLABS, Novartis Biome, Bayer Grants4Apps) or support of digital health companies via external organizations (i.e., Matter + Novo, J&J + Plug & Play)
COMMERCIALIZE: Typically BD&L partnerships with digital health technology organizations that leverage the life science organization’s commercialization capabilities to help bring the digital health technology to market (i.e., Novartis/Sandoz + Pear reSET-O)
COLLABORATE: Life science collaboration with digital health companies to leverage their technologies in an effort to achieve brand and customer goals (i.e., Boehringer Ingelheim + Propeller Health)
CO-DEVELOP: Jointly developing a digital health solution, utilizing an existing platform/asset from a digital health company and the R&D capabilities from a life science organization; typically includes governmental regulatory approval (i.e., Otsuka + Proteus, Pear/Thrive + Novartis in Schizophrenia)
If you would like additional perspective on these value models or Evolution Road’s point of view on driving commercial impact for pharma with digital health or digital marketing, “ask an expert” below.
A couple of weeks ago in April, on a rainy spring Friday, I had the pleasure of attending the Yale Digital Health Symposium in New Haven, Connecticut. It was well-attended, graciously hosted, and unlike the gloomy weather outside, ended up turning into a lovely afternoon of networking and learning from some most innovative minds in digital health today.
Topics covered were diverse, from AI, cognition, and mental health to new disruptive concepts like “digital pharmacies.”
Some of the highlights include Dr. Walter de Brouwer, CEO of doc.ai, all the way from Palo Alto, CA, who gave a discourse on the future of individualized medical data and the power of its potential applications. He called for a wide, yet safe, democratization of patient data, and explained how advanced-AI techniques could capture insights from this data and accelerate the development of new cures and research of obscure diseases.
Then Marc Appel, head of Orange Grove Bio, Jon Lanznar, VP of Client Services at Truveris, and David Light, CEO of Valisure delivered a panel about the current state of the pharmacy industry and the disruption caused by the host of new “digital pharmacies” gaining traction across the country. The acquisition of PillPack by Amazon, the launch of Capsure in NYC as well as the gigantic merger of CVS and Aetna were all discussed. Between the strategic moves made by larger players, the regulation, and the disruption already happening, this will be a fascinating industry to follow in the near future.
Finally, a panel composed of Eddie Martucci, CEO of Akili Interactive, Lynn Hamilton, COO of Talkspace, Dr. John Whang, Head of Cardio & Metabolism at J&J, and Dr. Scooter Plowman, Medical Director at Proteus delivered a wonderful discussion about the future of digital medicine and therapeutics. Eddie is building a company that is developing video games that both measure and improve cognitive health. Lynn runs an organization that is redefining the way we seek and receive mental therapy. Dr. Whang was the lead on the partnership between J&J and Apple Health that resulted in the widely acknowledged, year-long study of AFib using the Apple Watch. Finally, Dr. Plowman serves as the medical advisor of a company that is at the forefront of developing a scalable, commercially useable “smart” pill.
Unfortunately, this does not cover all the wonderful speakers who generously shared their time, and knowledge, with the audience that afternoon. We would like to thank them, and everyone mentioned above as well, for the time they shared with us. And a big thanks to Dr. Greg Licholai at the Yale School of Management and his staff for hosting such a wonderful event. We will be looking forward to the next one.
Want to learn more about how pharma can play a role in digital health? Reach out to one of our digital health experts: Jason Prignoli, email@example.com or leave us your contact below and we will schedule a discussion.
The most recent ATA (American Telemedicine Association) Conference explored how we should think about the value of telehealth as it becomes more mainstream.
Find out more at mHealthintelligence.
Let us know how we can get in touch below